Carl Accettura

Vice President & General Manager
PharmoRx Therapeutics

Carl Accettura is the Vice President & General Manager for PharmoRx Therapeutics, Inc., engaged in early stage development of novel therapy for the central nervous system, including Treatment Resistant Depression and Parkinson’s Disease.
Carl has 30 years of BioPharma industry experience with both Big Pharma - Pfizer, Roche, BMS – and Emergent Pharma companies - Anesta, Cephalon, Kyowa Hakko Kirin, Dainippon Sumitomo Pharma, Sunovion, and Braeburn Pharmaceuticals.
Carl has held executive level (VP) positions in the areas of supply chain, new product development and operations. He has overseen the development of end-to-end supply chain strategies, operations, and product launches across the US, Europe and Asia.
Carl successfully launched major branded drugs (Procardia XL, Diflucan, Norvasc, Zithromax, Zoloft, Cardura, Actiq and Latuda) globally. He did this by ensuring advanced commercial readiness through effective global and regional regulatory filings and approvals. He founded a consulting firm, Global Pharma Consulting, which was established to support small and medium-sized companies commercialize Rx products.
Carl’s most recent role was Vice President, Supply Chain at Braeburn Pharmaceuticals, where he developed the virtual supply chain for commercial launch readiness of a novel opioid implant product. He championed a novel trace and trace solution with partner, Covectra, for Probuphine’s strategic positioning as the “safest in the market”. He now supports Track & Trace solutions in the Life Sciences for Covectra.
Carl’s subject matter expertise in pharmaceutical new product launch and supply chain management makes him a sought after speaker. He speaks each semester at the Cornell University Enterprise Engineering Seminar.
Carl earned a B.S. with distinction from Cornell University in Mechanical Engineering. He also holds a M.S. from University of Illinois and a M.B.A from the Stern School at New York University.

Check out the incredible speaker line-up to see who will be joining Carl.

Download The Latest Agenda

Supply Chain Effeciency Across the Global Network

Tuesday, May 9th, 2017

14:10 Panel Discussion: The Spectrum Of Traditional Large Batch Molecules To Personalized Therapies And The Impact On The Supply Chain

Traditionally, the pharmaceutical supply chain has delivered scalable and conventional biopharmaceuticals. However, as more and more personalized products enter the market and immunology continues to deliver promising clinical therapies, smaller scale, alternative manufacturing and distribution approaches, methods of preservation, and fit with the endto- end supply chain will become the norm. With this continuum spanning from traditional large batch manufacturing of small molecule products to specialty treatments, there is significant differences in how supply chains should be managed and segmented. This panel will discuss:

Approaches needed to manage the variance of supply chains
What to expect from the integration of specialty pharmaceuticals, temperature controlled logistics, smaller volume production and more flexible manufacturing
Lessons learned and examples of how customized supply chains were managed